Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 7/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10127585 | 0.92 | LMNA (0.52) | LMNAACHEEPHX2DNM1MAOA | |
| SCHEMBL23847130 | 0.92 | LMNA (0.52) | LMNAACHEEPHX2DNM1MAOA | |
| SCHEMBL14175084 | 0.88 | LMNA (0.39) | LMNAACHECA12CA9CHRNB2 | |
| SCHEMBL25509703 | 0.85 | TSHR (0.42) | LMNACA12CA1CA9CHRNB2 | |
| SCHEMBL14946496 | 0.84 | CHRNB2 (0.42) | LMNACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22281741 | 0.84 | CHRNB2 (0.36) | LMNACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL14946492 | 0.83 | CHRM2 (0.35) | LMNAACHECHRNB2CHRNB4CHRNA3 | |
| SCHEMBL14946494 | 0.83 | KDM5A (0.36) | LMNAACHECHRNB2CHRNB4CHRNA3 | |
| SCHEMBL15254984 | 0.82 | CHRNB2 (0.34) | LMNAACHECHRNB2CHRNB4CHRNA3 | |
| SCHEMBL14190843 | 0.82 | CHRNB2 (0.34) | LMNACHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113966171-A | Fungicidal compositions | 先正达农作物保护股份公司 | 2022-01-21 | — | — | CN | claimed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
| US-20170151333-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-06-01 | — | — | US | disclosed |
| US-8865675-B2 | Compositions and methods for silencing apolipoprotein B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2014-10-21 | — | — | US | disclosed |
| US-20130123338-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20120053132-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-8048871-B2 | Inhibitors that when coadministered with a drug that undergoes in vivo degradation by cytochrome P450 enzyme, improves the pharmacokinetics, bioavailability and disease treatment such as of HIV, Hepatitis C virus, diabetes, epilepsy, cancer, depression; amide or sulfonamide-functional benzofurans | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110098237-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20080113945-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113945-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | LMNA 1884/4885ACHE 317/4885CA12 2922/4885 |
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | LMNA 4444/4885ACHE 4885/4885CA12 4858/4885 |
| US-20130123338-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | LMNA 301/4885ACHE 4857/4885CA12 3534/4885 |
| US-20120053132-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | LMNA 1884/4885ACHE 317/4885CA12 2922/4885 |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | APOB, LDLR, APOL1 | LMNA 119/4885ACHE 4707/4885CA12 4208/4885 |
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | LMNA 1898/4885ACHE 4785/4885CA12 3384/4885 |
| US-20170151333-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | LMNA 301/4885ACHE 4857/4885CA12 3534/4885 |
| US-20110098237-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | CYP2E1, CYP3A43, CYP3A5 | LMNA 1905/4885ACHE 528/4885CA12 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.